vascular inflammation News
-
Diesel Exhaust + Cholesterol = Cardiovascular Disease
LOS ANGELES, California, July 26, 2007 (ENS) - Exposure to a combination of diesel exhaust and high blood cholesterol increases the risk for heart attack and stroke far more than exposure to either factor alone, new research reveals. The results indicate that controlling air pollution may prove to be a powerful tool for preventing cardiovascular disease. Published in today's edition of the ...
-
Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company focused on the development of regenerative medicines to save lives, announced today that the Biomedical Advanced Research and Development Authority (BARDA) part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services executed options to add $10.4 ...
-
Inscopix Expands Applications with Blood Flow Imaging to Study Relationship between Brain Activity and Vascular Dynamics
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, stroke and other debilitating ...
-
Gesynta Pharma reports positive Phase I results with lead candidate GS-248 for microvascular disease at EULAR 2020
Gesynta Pharma AB ("Gesynta"), a clinical stage company developing novel anti-inflammatory agents, today announced that the results from the successfully completed First-in-Human clinical study with its lead candidate GS-248 for the treatment of microvascular disease have been presented at the EULAR 2020 E-Congress. Following these results, Gesynta now intends to commence a Phase II study in ...
-
Gesynta Pharma announces positive Phase I results with GS-248 for the treatment of microvascular disease - data to be presented at EULAR congress
Gesynta Pharma AB ("Gesynta") announces the completion and positive results of a first clinical study with GS-248. The purpose of the study was to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties of GS-248 after single and multiple ascending doses to healthy subjects. The results support the further clinical development of GS-248 in microvascular dysfunction and a ...
-
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS-248 in patients with systemic sclerosis
Gesynta Pharma AB today announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis - a debilitating autoimmune disease that causes serious damage to the microvasculature. This proof-of-concept study will investigate the safety of GS-248 and its efficacy on Raynaud's phenomenon and peripheral blood flow in this ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you